X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of “Moderate Buy” by Analysts

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $28.8750.

A number of research analysts recently issued reports on XFOR shares. Guggenheim began coverage on X4 Pharmaceuticals in a research note on Monday, March 9th. They set a “buy” rating and a $12.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research note on Monday, December 29th. Zacks Research downgraded shares of X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 26th. Stifel Nicolaus set a $10.00 price target on shares of X4 Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 5th. Finally, Wall Street Zen raised shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday.

Institutional Investors Weigh In On X4 Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its holdings in X4 Pharmaceuticals by 20.3% during the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after acquiring an additional 22,485 shares during the period. Rhumbline Advisers boosted its stake in shares of X4 Pharmaceuticals by 5.4% in the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after acquiring an additional 9,690 shares during the period. Jane Street Group LLC grew its position in shares of X4 Pharmaceuticals by 112.5% during the second quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock worth $185,000 after purchasing an additional 51,544 shares in the last quarter. Vanguard Group Inc. grew its position in shares of X4 Pharmaceuticals by 77.0% during the third quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock worth $1,404,000 after purchasing an additional 178,593 shares in the last quarter. Finally, Palumbo Wealth Management LLC bought a new stake in X4 Pharmaceuticals during the 3rd quarter valued at approximately $326,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals News Roundup

Here are the key news stories impacting X4 Pharmaceuticals this week:

• Positive Sentiment: Brookline materially improved its FY2026 EPS view (from -$1.50 to -$1.04), a smaller near‑term loss that suggests a faster path toward profitability. Brookline Cap M FY2026 estimate
• Positive Sentiment: Brookline raised its FY2027 EPS forecast (from -$1.70 to -$0.96), reducing multi‑year downside and improving the medium‑term outlook. Brookline Cap M FY2027 estimate
• Positive Sentiment: Brookline lifted its FY2028 estimate (from -$0.42 to -$0.24), another sign of improving expected margins in later years. Brookline Cap M FY2028 estimate
• Positive Sentiment: Brookline published a long‑range FY2030 EPS projection of $2.85, signaling significant upside potential if X4 hits longer‑term commercialization and scaling assumptions. Brookline Cap M FY2030 estimate
• Neutral Sentiment: Brookline provided updated quarterly EPS forecasts for 2026 (Q1: -$0.20, Q2: -$0.23, Q3: -$0.27, Q4: -$0.34) that set expectations for near‑term performance but are routine analyst guidance updates rather than company‑driven news. Brookline Cap M quarterly estimates
• Negative Sentiment: Brookline cut its FY2029 EPS forecast sharply (from $1.52 to $0.85), lowering medium‑term upside and indicating the analyst reduced confidence in the timing/scale of revenue or margin improvements for that year. Brookline Cap M FY2029 revision

X4 Pharmaceuticals Stock Performance

NASDAQ:XFOR opened at $4.28 on Friday. The stock has a 50-day simple moving average of $3.67 and a two-hundred day simple moving average of $3.62. X4 Pharmaceuticals has a 52-week low of $1.35 and a 52-week high of $9.56. The company has a debt-to-equity ratio of 0.41, a quick ratio of 5.48 and a current ratio of 10.16. The firm has a market capitalization of $389.14 million, a PE ratio of -0.99 and a beta of 0.43.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings results on Tuesday, March 17th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.14. X4 Pharmaceuticals had a negative return on equity of 115.27% and a negative net margin of 225.55%.The business had revenue of $2.57 million during the quarter, compared to analysts’ expectations of $1.68 million. Analysts forecast that X4 Pharmaceuticals will post -0.68 EPS for the current year.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.